Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid a stimulate robust cellular and humoral immune responses

Simple item page
dc.contributor.authorRizwan, SBen_AU
dc.contributor.authorMcBurney, WTen_AU
dc.contributor.authorYoung, Ken_AU
dc.contributor.authorHanley, TLen_AU
dc.contributor.authorBoyd, BJen_AU
dc.contributor.authorRades, Ten_AU
dc.contributor.authorHook, Sen_AU
dc.date.accessioned2013-03-12T01:29:50Zen_AU
dc.date.available2013-03-12T01:29:50Zen_AU
dc.date.issued2013-01-10en_AU
dc.date.statistics2013-03-12en_AU
dc.description.abstractNew generation vaccines increasingly utilize highly purified peptides and proteins as the target antigen, however these are often poorly immunogenic. One of the most promising strategies for improving immunogenicity of such subunit vaccines is through incorporation into particulate carriers. Here we report the preparation, physicochemical characterization and in vivo immunological activity of cubosomes, a novel lipid-based nanostructured particulate carrier, modified to include the Toll-like receptor agonists monophosphoryl lipid A and imiquimod. The immunological activity of cubosome formulations was compared to that of liposome and alum formulations. Sustained release of the model antigen ovalbumin (Ova) was observed in vitro and in vivo from cubosomes. Cubosomes + adjuvants induced robust CD8(+) and CD4(+) T cell proliferation and interferon-gamma production, as well as the production of Ova-specific antibodies. Cubosomes+ adjuvants were more efficient at generating Ova-specific cellular responses and were equally as effective in generating humoral responses when compared to liposomes + adjuvants and alum. Overall, the results show that cubosomes have the potential to act as effective sustained release vaccine delivery systems. © 2013, Elsevier Ltd.en_AU
dc.identifier.citationRizwan, S.B., McBurney, W.T., Young, K., Hanley, T., Boyd, B.J., Rades, T., & Hook, S. (2013). Cubosomes containing the adjuvants imiquimod and monophosphoryl lipid a stimulate robust cellular and humoral immune responses. Journal of Controlled Release, 165(1), 16-21. doi:10.1016/j.jconrel.2012.10.020en_AU
dc.identifier.govdoc4888en_AU
dc.identifier.issn0168-3659en_AU
dc.identifier.issue1en_AU
dc.identifier.journaltitleJournal of Controlled Releaseen_AU
dc.identifier.pagination16-21en_AU
dc.identifier.urihttp://dx.doi.org/10.1016/j.jconrel.2012.10.020en_AU
dc.identifier.urihttp://apo.ansto.gov.au/dspace/handle/10238/4517en_AU
dc.identifier.volume165en_AU
dc.language.isoenen_AU
dc.publisherElsevieren_AU
dc.subjectDispersionsen_AU
dc.subjectLiposomesen_AU
dc.subjectIn vivoen_AU
dc.subjectOvalbuminen_AU
dc.titleCubosomes containing the adjuvants imiquimod and monophosphoryl lipid a stimulate robust cellular and humoral immune responsesen_AU
dc.typeJournal Articleen_AU
Files
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Journal Articles